MetaVia Inc. (NASDAQ:MTVA – Free Report) – HC Wainwright issued their Q4 2024 earnings estimates for MetaVia in a report released on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will post earnings per share of ($0.74) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s FY2025 earnings at ($2.61) EPS and FY2026 earnings at ($2.73) EPS.
MetaVia Stock Performance
NASDAQ MTVA opened at $2.03 on Wednesday. MetaVia has a 1 year low of $1.51 and a 1 year high of $6.75.
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Work and Play: Investing in the Rise of Bleisure Travel
- 5 discounted opportunities for dividend growth investors
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
